A research study looking at long-term treatment with Mim8 in people with haemophilia A(NN7769-4532)
- Conditions
- Participants with haemophilia A with or without FVIII inhibitors
- Registration Number
- JPRN-jRCT2041230047
- Lead Sponsor
- Esaki Risa
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 425
1.Informed consent obtained before any study related activities. Study related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
2.Male or female with diagnosis of congenital haemophilia A based on medical records.
3.Ongoing participation in study NN7769-4513, NN7769-4514, NN7769-4516, or NN7769 4728 at the time of transfer. Participant should qualify either of the following criteria:
a.Participant from study NN7769-4513, who has participated in the extension part of the study for at least 12 weeks prior to enrolment in study NN7769-4532, or,
b.Participant has completed the end of treatment visit for study NN7769-4514, NN7769 4516, or NN7769-4728.
4.Participant and/or participant's parent(s)/participant's legally acceptable representative (LAR) willingness and ability to comply with scheduled visits and study procedures, including the completion of diary.
1.Any disorder, except for conditions associated with haemophilia, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
2.Participant who has discontinued or been withdrawn from studies NN7769-4513, NN7769-4514, NN7769-4516, or NN7769-4728.
3.Previous participation in this study. Participation is defined as signed informed consent.
4.Female who is pregnant, breast-feeding or intends to become pregnant.
5.Female of child-bearing potential and not using a highly effective contraceptive method (highly effective contraceptive measures as defined in Appendix 4 or as required by local regulation or practice).
6.Participation (i.e., signed informed consent) in any interventional, clinical study (except from study NN7769-4513, NN7769-4514, NN7769-4516, or NN7769-4728) of an approved or non-approved investigational medicinal product.
7. Any planned majors surgery, during part1 of the study, For definition of major surgery see Table6-7.
8.Mental incapacity, unwillingness to cooperate, or a language barrier precluding adequate understanding and cooperation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umber of treatment-emergent adverse events (TEAEs)
- Secondary Outcome Measures
Name Time Method